PolyPid Ltd. (PYPD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Petah Tikva, Israel. The current CEO is Dikla Czaczkes Akselbrad.
PYPD has IPO date of 2020-06-26, 57 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $45.04M.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
